Improving the efficacy of antibody-based cancer therapies

Nat Rev Cancer. 2001 Nov;1(2):118-29. doi: 10.1038/35101072.

Abstract

A quarter of a century after their advent, monoclonal antibodies have become the most rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases, including cancer. Although antibodies have yet to achieve the ultimate goal of curing cancer, many innovative approaches stand poised to improve the efficacy of antibody-based therapies.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies / immunology
  • Antibodies / therapeutic use*
  • Antibodies, Bispecific / therapeutic use
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antibodies, Neoplasm / immunology
  • Antibodies, Neoplasm / therapeutic use
  • Antibody-Dependent Cell Cytotoxicity
  • Antigens, Neoplasm / immunology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Combined Modality Therapy
  • Cytokines / administration & dosage
  • Cytokines / therapeutic use
  • Drug Delivery Systems
  • Humans
  • Immunization, Passive
  • Immunoconjugates / therapeutic use
  • Immunotherapy / methods
  • Immunotoxins / therapeutic use
  • Liposomes
  • Mice
  • Neoplasm Proteins / antagonists & inhibitors
  • Neoplasm Proteins / immunology
  • Neoplasm, Residual
  • Neoplasms / drug therapy
  • Neoplasms / immunology
  • Neoplasms / pathology
  • Neoplasms / radiotherapy
  • Neoplasms / therapy*
  • Neovascularization, Pathologic / immunology
  • Neovascularization, Pathologic / therapy
  • Prodrugs / administration & dosage
  • Protein Engineering
  • Radioimmunotherapy
  • Recombinant Fusion Proteins / immunology
  • Recombinant Fusion Proteins / therapeutic use
  • Rituximab
  • Trastuzumab
  • Treatment Outcome
  • Xenograft Model Antitumor Assays

Substances

  • Antibodies
  • Antibodies, Bispecific
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antibodies, Neoplasm
  • Antigens, Neoplasm
  • Cytokines
  • Immunoconjugates
  • Immunotoxins
  • Liposomes
  • Neoplasm Proteins
  • Prodrugs
  • Recombinant Fusion Proteins
  • Rituximab
  • Trastuzumab